BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

Table 1

Completed clinical trials evaluating potential drug targets of BRCA1.

Drug class	Compound	Phase	Study population
PARP inhibitors	KU-0059436 (AZD2281)	Phase I	BRCA1/2 germline mutation in advanced breast and EOC [23]
HDAC inhibitors	SAHA (vorinostat)	Phase II	Recurrent EOC [24]
CHK inhibitors	UCN-01 (staurosporine derivative) in combination with topotecan	Phase I	Advanced solid tumors, including EOC [25]
	UCN-01 in combination with topotecan	Phase II	Recurrent EOC [26]
Proteasome inhibitors	PS-341 (bortezomib) in combination with carboplatin	Phase I	Recurrent EOC [27]
	PS-341 in combination with carboplatin	Phase I	Platinum/taxane resistant EOC [28]
	PS-341	Phase II	Recurrent, platinum-sensitive EOC [29]
	PS-341 in combination with paclitaxel	Phase I	Advanced solid tumours, including EOC [30]